Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marine Andreani

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancer Immunology, Immunotherapy : CII|June 22, 2021
Immune checkpoint inhibitors-induced nephropathy: a French national surveyAlexandre O Gérard, Marine Andreani, Audrey Fresse, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 26, 2019
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous NephropathyBarbara Seitz-Polski, Karine Dahan, Hanna Debiec, et al.
Clinical Kidney Journal|September 26, 2022
Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control studyAlexandre O Gérard, Susana Barbosa, Nadège Parassol, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancer Immunology, Immunotherapy : CII|June 22, 2021
Immune checkpoint inhibitors-induced nephropathy: a French national surveyAlexandre O Gérard, Marine Andreani, Audrey Fresse, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 26, 2019
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous NephropathyBarbara Seitz-Polski, Karine Dahan, Hanna Debiec, et al.
Clinical Kidney Journal|September 26, 2022
Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control studyAlexandre O Gérard, Susana Barbosa, Nadège Parassol, et al.
Pageof 2